TherapeuticsMD (TXMD) Misses Q3 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
TherapeuticsMD Announces Third Quarter 2021 Financial Results
November 11, 2021 6:50 AM EST- Quarterly total net product revenue of $24.5 million, an increase of 41.1% over Q3 2020 -
- ANNOVERA® TRx of 8,351, an increase of 62.7% over Q3 2020 -
- Cost savings initiative to reduce SG&A by $40 million in 2022; anticipated additional savings of approximately $20 million annualized tied to the divestiture of vitaCare -
- Hugh ODowd, President, to become Chief Executive Officer; Robert Finizio appointed Vice Chair of the Board -
- Conference call scheduled for 8:30 a.m. ET today -
BOCA RATON, Fla.--(BUSINESS... More
